# LAPTM5

## Overview
LAPTM5 (lysosomal-associated protein transmembrane 5) is a gene that encodes a multispanning transmembrane protein predominantly expressed in hematopoietic cells. The protein, also referred to as lysosomal protein transmembrane 5, is primarily localized in the late endosome and lysosome, where it plays a significant role in lysosomal function and vesicle trafficking. As a transmembrane protein, LAPTM5 is involved in the regulation of T cell receptor (TCR) expression and activation, acting as a negative regulator by promoting the degradation of the CD3ζ chain, a component of the TCR complex. This function is crucial for maintaining immune homeostasis and preventing autoimmunity. Additionally, LAPTM5 interacts with various proteins, including ubiquitin ligases such as Nedd4 and Smurf2, to facilitate its lysosomal targeting and protein degradation activities. The gene's expression and interactions have been implicated in several diseases, including cancer and familial Waldenström macroglobulinemia, highlighting its potential as a therapeutic target (Ouchida2008A; Kawai2014LAPTM5; Han2023LAPTM5; Roccaro2016Exome).

## Structure
LAPTM5 is a multispanning transmembrane protein primarily expressed in hematopoietic cells. It is located in the late endosome and lysosome, playing a role in lysosomal function and vesicle trafficking. The protein contains five membrane-spanning segments, which are integral to its function in lysosomal transport (Pak2006Transport; Kawano2012A).

LAPTM5 features three polyproline-tyrosine (PY) motifs and a ubiquitin-interacting motif (UIM) at its C terminus. The PY motifs are crucial for interaction with the ubiquitin ligase Nedd4, facilitating the sorting of LAPTM5 to lysosomes. The third PY motif is particularly important for binding to Nedd4, although the first PY motif also contributes to this interaction (Pak2006Transport). The UIM is essential for binding ubiquitin and ubiquitinated proteins, such as GGA3, which is necessary for LAPTM5's translocation from the Golgi to the lysosome (Pak2006Transport).

LAPTM5 also contains a C-terminal SxV motif, a putative PDZ-binding motif, which may play a role in its interactions with other proteins involved in cellular trafficking (Pak2006Transport). The protein can be ubiquitinated by Nedd4, although this modification is not required for its lysosomal localization (Pak2006Transport). There is no well-defined quaternary structure for LAPTM5, as it functions as a single polypeptide chain.

## Function
LAPTM5 (lysosomal protein transmembrane 5) is a lysosomal protein primarily expressed in hematopoietic cells, where it plays a crucial role in regulating T cell receptor (TCR) expression and T cell activation. LAPTM5 promotes the degradation of the CD3ζ chain, a component of the TCR complex, by facilitating its transport to lysosomes. This degradation process is essential for controlling TCR expression on the cell surface, thereby regulating T cell activation and preventing hyperactivation and autoimmunity (Ouchida2008A; Kawai2014LAPTM5).

In LAPTM5-deficient T cells, there is an increase in surface TCR expression and CD3ζ protein levels, leading to enhanced T cell proliferation and cytokine production. This suggests that LAPTM5 acts as a negative regulator of TCR signaling by promoting CD3ζ degradation (Ouchida2008A). LAPTM5 targets intracellular CD3ζ for lysosomal degradation, a process that occurs independently of TCR signaling and involves the Golgi apparatus as a key site for targeting CD3ζ (Kawai2014LAPTM5).

LAPTM5's function is distinct from other proteins like SLAP and c-Cbl, which regulate the fate of internalized TCR complexes. This dual regulatory mechanism ensures strict control of surface TCR expression, crucial for normal T-cell development and activation (Kawai2014LAPTM5).

## Clinical Significance
LAPTM5 has been implicated in various diseases due to its altered expression and interactions. In breast cancer, LAPTM5 is overexpressed in cancerous tissues compared to non-cancerous ones, correlating with poor prognosis and higher tumor grades. Its overexpression promotes malignant phenotypes such as cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) through the activation of the Wnt/β-catenin signaling pathway. FOXP3, a transcription factor, negatively regulates LAPTM5, suggesting a potential therapeutic target (Han2023LAPTM5).

In renal cell carcinoma (RCC), LAPTM5 is upregulated and associated with higher histological grades and metastasis, particularly lung-specific metastasis. It interacts with WWP2 to mediate the degradation of BMPR1A, a BMP receptor, promoting metastasis by interfering with anti-metastatic signals (Jiang2022Lysosomal).

LAPTM5 is also involved in familial Waldenström macroglobulinemia (WM), where a germ line variant, LAPTM5 c403t/P135S, is more prevalent in familial cases. This variant may serve as a genetic marker for WM, affecting disease biology through its interaction with other immune-related genes (Roccaro2016Exome).

## Interactions
LAPTM5 interacts with several proteins, playing a crucial role in lysosomal targeting and protein degradation. It forms a complex with the ubiquitin ligase Nedd4 and the adaptor protein GGA3, which is essential for its transport from the Golgi to lysosomes. This interaction involves the binding of LAPTM5's PY motifs to the WW domains of Nedd4, facilitating the recruitment of ubiquitinated GGA3 to LAPTM5's ubiquitin-interacting motif (UIM) (Pak2006Transport). 

LAPTM5 also interacts with Smurf2, another E3-ubiquitin ligase, which is involved in the degradation of TGFβ signaling components (Jun2017Ectopic). In the context of HIV-1 infection, LAPTM5 restricts viral infectivity by transporting the HIV-1 envelope glycoproteins to lysosomes for degradation. The viral protein Vpr counteracts this by promoting LAPTM5 degradation through a DCAF1/proteasome-dependent pathway, allowing the virus to evade this restriction (Zhao2021Vpr).

LAPTM5 also interacts with the A20 protein, a negative regulator of NF-κB activation, suggesting a role in proinflammatory signaling pathways. This interaction occurs in the endolysosomal system and is independent of external stimuli (Glowacka2012LAPTM5).


## References


[1. (Kawai2014LAPTM5) Yohei Kawai, Rika Ouchida, Sho Yamasaki, Leonard Dragone, Takeshi Tsubata, and Ji‐Yang Wang. Laptm5 promotes lysosomal degradation of intracellular cd3ζ but not of cell surface cd3ζ. Immunology &amp; Cell Biology, 92(6):527–534, March 2014. URL: http://dx.doi.org/10.1038/icb.2014.18, doi:10.1038/icb.2014.18. This article has 21 citations.](https://doi.org/10.1038/icb.2014.18)

[2. (Zhao2021Vpr) Li Zhao, Shumei Wang, Meng Xu, Yang He, Xiaowei Zhang, Ying Xiong, Hong Sun, Haibo Ding, Wenqing Geng, Hong Shang, and Guoxin Liang. Vpr counteracts the restriction of laptm5 to promote hiv-1 infection in macrophages. Nature Communications, June 2021. URL: http://dx.doi.org/10.1038/s41467-021-24087-8, doi:10.1038/s41467-021-24087-8. This article has 30 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-24087-8)

[3. (Jun2017Ectopic) Do Youn Jun, Hyejin Kim, Won Young Jang, Ji Young Lee, Kiyoshi Fukui, and Young Ho Kim. Ectopic overexpression of laptm5 results in lysosomal targeting and induces mcl-1 down-regulation, bak activation, and mitochondria-dependent apoptosis in human hela cells. PLOS ONE, 12(5):e0176544, May 2017. URL: http://dx.doi.org/10.1371/journal.pone.0176544, doi:10.1371/journal.pone.0176544. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0176544)

[4. (Kawano2012A) Yohei Kawano, Rika Ouchida, Ji-Yang Wang, Soichiro Yoshikawa, Mutsumi Yamamoto, Daisuke Kitamura, and Hajime Karasuyama. A novel mechanism for the autonomous termination of pre-b cell receptor expression via induction of lysosome-associated protein transmembrane 5. Molecular and Cellular Biology, 32(21):4462–4471, November 2012. URL: http://dx.doi.org/10.1128/mcb.00531-12, doi:10.1128/mcb.00531-12. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00531-12)

[5. (Pak2006Transport) Youngshil Pak, Wioletta K. Glowacka, M. Christine Bruce, Nam Pham, and Daniela Rotin. Transport of laptm5 to lysosomes requires association with the ubiquitin ligase nedd4, but not laptm5 ubiquitination. The Journal of Cell Biology, 175(4):631–645, November 2006. URL: http://dx.doi.org/10.1083/jcb.200603001, doi:10.1083/jcb.200603001. This article has 85 citations.](https://doi.org/10.1083/jcb.200603001)

[6. (Jiang2022Lysosomal) Bo Jiang, Xiaozhi Zhao, Wei Chen, Wenli Diao, Meng Ding, Haixiang Qin, Binghua Li, Wenmin Cao, Wei Chen, Yao Fu, Kuiqiang He, Jie Gao, Mengxia Chen, Tingsheng Lin, Yongming Deng, Chao Yan, and Hongqian Guo. Lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating bmpr1a lysosomal degradation. Nature Communications, July 2022. URL: http://dx.doi.org/10.1038/s41467-022-31783-6, doi:10.1038/s41467-022-31783-6. This article has 17 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-022-31783-6)

[7. (Han2023LAPTM5) Sijia Han, Xueying Jin, Tianyu Hu, and Feng Chi. Laptm5 regulated by foxp3 promotes the malignant phenotypes of breast cancer through activating the wnt/β‑catenin pathway. Oncology Reports, February 2023. URL: http://dx.doi.org/10.3892/or.2023.8497, doi:10.3892/or.2023.8497. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2023.8497)

[8. (Glowacka2012LAPTM5) Wioletta K. Glowacka, Philipp Alberts, Rika Ouchida, Ji-Yang Wang, and Daniela Rotin. Laptm5 protein is a positive regulator of proinflammatory signaling pathways in macrophages. Journal of Biological Chemistry, 287(33):27691–27702, August 2012. URL: http://dx.doi.org/10.1074/jbc.M112.355917, doi:10.1074/jbc.m112.355917. This article has 91 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M112.355917)

[9. (Roccaro2016Exome) Aldo M. Roccaro, Antonio Sacco, Jiantao Shi, Marco Chiarini, Adriana Perilla-Glen, Salomon Manier, Siobhan Glavey, Yosra Aljawai, Yuji Mishima, Yawara Kawano, Michele Moschetta, Mick Correll, Ma. Reina Improgo, Jennifer R. Brown, Luisa Imberti, Giuseppe Rossi, Jorge J. Castillo, Steven P. Treon, Matthew L. Freedman, Eliezer M. Van Allen, Winston Hide, Elaine Hiller, Irene Rainville, and Irene M. Ghobrial. Exome sequencing reveals recurrent germ line variants in patients with familial waldenström macroglobulinemia. Blood, 127(21):2598–2606, May 2016. URL: http://dx.doi.org/10.1182/blood-2015-11-680199, doi:10.1182/blood-2015-11-680199. This article has 22 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2015-11-680199)

[10. (Ouchida2008A) Rika Ouchida, Sho Yamasaki, Masaki Hikida, Keiji Masuda, Kiyoko Kawamura, Akihiko Wada, Shigenobu Mochizuki, Masatoshi Tagawa, Akemi Sakamoto, Masahiko Hatano, Takeshi Tokuhisa, Haruhiko Koseki, Takashi Saito, Tomohiro Kurosaki, and Ji-Yang Wang. A lysosomal protein negatively regulates surface t cell antigen receptor expression by promoting cd3ζ-chain degradation. Immunity, 29(1):33–43, July 2008. URL: http://dx.doi.org/10.1016/j.immuni.2008.04.024, doi:10.1016/j.immuni.2008.04.024. This article has 61 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.immuni.2008.04.024)